Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Purchased by Teamwork Financial Advisors LLC

Teamwork Financial Advisors LLC lifted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 32.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,930 shares of the medical equipment provider’s stock after acquiring an additional 6,299 shares during the period. Intuitive Surgical makes up 1.6% of Teamwork Financial Advisors LLC’s portfolio, making the stock its 21st biggest position. Teamwork Financial Advisors LLC’s holdings in Intuitive Surgical were worth $10,348,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Intuitive Surgical by 0.7% during the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock worth $8,730,184,000 after purchasing an additional 196,316 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Intuitive Surgical by 1.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after purchasing an additional 272,741 shares in the last quarter. Edgewood Management LLC increased its stake in shares of Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after buying an additional 374,667 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Intuitive Surgical by 2.0% in the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock valued at $1,516,222,000 after acquiring an additional 88,977 shares in the last quarter. Finally, Norges Bank bought a new position in Intuitive Surgical during the 4th quarter valued at $1,313,238,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 0.9 %

ISRG stock traded down $4.00 during trading hours on Thursday, hitting $434.81. 826,374 shares of the stock traded hands, compared to its average volume of 1,473,994. The stock has a 50-day simple moving average of $407.60 and a 200 day simple moving average of $385.43. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $448.10. The company has a market cap of $154.23 billion, a P/E ratio of 78.49, a P/E/G ratio of 5.67 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the prior year, the firm earned $1.00 EPS. The firm’s quarterly revenue was up 11.5% on a year-over-year basis. Analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on ISRG. BTIG Research boosted their price objective on Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a report on Friday, April 19th. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. Stifel Nicolaus increased their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target on the stock. Finally, Jefferies Financial Group boosted their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $404.79.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 1,498 shares of the company’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $369.92, for a total transaction of $554,140.16. Following the completion of the sale, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,037,149.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Robert Desantis sold 1,498 shares of the firm’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $369.92, for a total transaction of $554,140.16. Following the completion of the sale, the executive vice president now owns 5,507 shares in the company, valued at approximately $2,037,149.44. The disclosure for this sale can be found here. Insiders have sold a total of 17,956 shares of company stock valued at $6,927,011 in the last three months. Insiders own 0.80% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.